Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways

Archives of Otolaryngology - Head and Neck Surgery

Volumn 137, Issue 11, 2011, Pages 1146-1153

  Kamat, Ameet ^a   Rajoria, Shilpi ^b   George, Andrea ^b   Suriano, Robert ^b   Shanmugam, Arulkumaran ^b   Megwalu, Uchechukwu ^a   Prakash, Pradeep Bangalore ^b   Tiwari, Raj ^b   Schantz, Stimson ^a  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL; CELL INTERACTION; CELL MIGRATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; THYROID CELL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DNA, NEOPLASM; ENDOTHELIUM, VASCULAR; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81855168358     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archoto.2011.194     Document Type: Article

References (13)

1. Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010;20(1):33-41.
2. Levi F, Franceschi S, Gulie C, Negri E, La Vecchia C. Female thyroid cancer: the role of reproductive and hormonal factors in Switzerland. Oncology. 1993; 50(4):309-315. (Pubitemid 23193926)
3. Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1174- 1182.
4. Suriano R, Chaudhuri D, Johnson RS, et al. 17β-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Res. 2008;68(15):6038- 6042.
5. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000;166(3):475- 480.
6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027. (Pubitemid 46202320)
7. Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene. 2004;23(2):434-445. (Pubitemid 38174998)
8. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997;82(11):3741-3747. (Pubitemid 27509365)
9. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci. 2003;28(9):488-494. (Pubitemid 38340413)
10. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381-395. (Pubitemid 34214843)
11. Holmqvist K, Cross MJ, Rolny C, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267- 22275. (Pubitemid 38679423)
12. Soh EY, Sobhi SA, Wong MG, et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery. 1996;120(6):944-947. (Pubitemid 26418770)
13. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 2000;128(6): 1059-1066.